Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort
Masatake Kobayashi,João Pedro Ferreira,Duarte Kevin,Emmanuel Bresso,Olivier Huttin,Erwan Bozec,Hans‐Peter Brunner La Rocca,Christian Delles,Andrew L. Clark,Frank Edelmann,Arantxa González,Stephane Heymans,Pierpaolo Pellicori,Johannes Petutschnigg,Job A.J. Verdonschot,Patrick Rossignol,John G.F. Cleland,Faiez Zannad,Nicolas Girerd,on behalf of the HOMAGE Trial Committees and Investigators
DOI: https://doi.org/10.1002/ejhf.3202
2024-03-27
European Journal of Heart Failure
Abstract:In individuals at risk of developing heart failure (HF) (HOMAGE), left atrial volume index (LAVi) showed associations with matrix metallopeptidase‐2 (MMP‐2), insulin‐like growth factor binding protein‐2 (IGFBP‐2), and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). These associations were validated in an independent community‐based cohort (STANISLAS). Among these biomarkers, spironolactone reduced concentrations of MMP‐2 and NT‐proBNP over a 9‐month period in HOMAGE participants, irrespective of baseline LAVi. Additionally, spironolactone significantly decreased LAVi, improved left ventricular ejection fraction (LVEF), reduced E/e′, blood pressure, and serum procollagen type I C‐terminal propeptide (PICP) concentration, regardless of baseline LAVi. LA, left atrial; MRA, mineralocorticoid receptor antagonist; SBP, systolic blood pressure. Aims High left ventricular filling pressure increases left atrial volume and causes myocardial fibrosis, which may decrease with spironolactone. We studied clinical and proteomic characteristics associated with left atrial volume indexed by body surface area (LAVi), and whether LAVi influences the response to spironolactone on biomarker expression and clinical variables. Methods and results In the HOMAGE trial, where people at risk of heart failure were randomized to spironolactone or control, we analysed 421 participants with available LAVi and 276 proteomic measurements (Olink) at baseline, month 1 and 9 (mean age 73 ± 6 years; women 26%; LAVi 32 ± 9 ml/m2). Circulating proteins associated with LAVi were also assessed in asymptomatic individuals from a population‐based cohort (STANISLAS; n = 1640; mean age 49 ± 14 years; women 51%; LAVi 23 ± 7 ml/m2). In both studies, greater LAVi was significantly associated with greater left ventricular masses and volumes. In HOMAGE, after adjustment and correction for multiple testing, greater LAVi was associated with higher concentrations of matrix metallopeptidase‐2 (MMP‐2), insulin‐like growth factor binding protein‐2 (IGFBP‐2) and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) (false discovery rates [FDR] <0.05). These associations were externally replicated in STANISLAS (all FDR 0.10). Spironolactone also significantly reduced LAVi, improved left ventricular ejection fraction, lowered E/e', blood pressure and serum procollagen type I C‐terminal propeptide (PICP) concentration, a collagen synthesis marker, regardless of baseline LAVi (pinteraction > 0.10). Conclusion In individuals without heart failure, LAVi was associated with MMP‐2, IGFBP‐2 and NT‐proBNP. Spironolactone reduced these biomarker concentrations as well as LAVi and PICP, irrespective of left atrial size.
cardiac & cardiovascular systems